Atrys Health, S.A. (BME:ATRY)
Spain · Delayed Price · Currency is EUR 2.560
0.00 (0.00%)
Aug 27, 2026, 5:35 PM CET
Atrys Health Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 144.31 | 144.31 | 134.88 | 206.1 | 163.2 | 123.85 |
Revenue Growth | -36.21% | 7.00% | -34.56% | 26.28% | 31.77% | 266.34% |
Gross Profit Gross Profit Growth | 24.92 | 24.92 | 30.34 | 57.15 | 46.95 | 34.19 |
Operating Income Operating Income Growth | -10.4 | -10.4 | -0.16 | -1.58 | -10.75 | -4.03 |
Net Income Net Income Growth | -100.3 | -100.3 | -31.77 | -45.59 | -23.15 | -23.26 |
Earnings Per Share EPS Growth | -1.32 | -1.32 | -0.42 | -0.60 | -0.34 | -0.46 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Medicine Precision - Diagnosis Medicine Precision - Diagnosis Growth | 68.84 | 68.84 | 71.39 | - | - |
Medicine Precision - Oncology Medicine Precision - Oncology Growth | 75.48 | 75.48 | 63.49 | 58.03 | 35.42 |
Total Total Growth | 144.31 | 144.31 | 134.88 | 206.1 | 163.2 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 13.58 | 13.58 | 20.88 | 42.38 | 36.06 | 35.23 |
Total Debt Total Debt Growth | 257.87 | 257.87 | 255.4 | 253.93 | 241.15 | 200.58 |
Net Cash (Debt) Net Cash Growth | -244.29 | -244.29 | -234.52 | -211.55 | -205.09 | -165.35 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -3.22 | -3.22 | -3.09 | -2.79 | -3.01 | -3.29 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -1.56 | -1.56 | 3 | 5.7 | -15.43 | 4.69 |
Capital Expenditures CapEx Growth | -6.49 | -6.49 | -4.25 | -6.25 | -6.77 | -4.22 |
Free Cash Flow Free Cash Flow Growth | -8.05 | -8.05 | -1.25 | -0.55 | -22.2 | 0.47 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 17.27% | 17.27% | 22.50% | 27.73% | 28.77% | 27.60% |
Operating Margin | -7.21% | -7.21% | -0.12% | -0.77% | -6.59% | -3.26% |
Pretax Margin | -38.94% | -38.94% | -25.67% | -16.35% | -16.42% | -20.09% |
Profit Margin | -69.50% | -69.50% | -23.56% | -22.12% | -14.18% | -18.78% |
FCF Margin | -5.58% | -5.58% | -0.93% | -0.27% | -13.60% | 0.38% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | 44.28 | 17.00 | 156.74 | 25.81 | 29.58 | 36.01 |
P/FCF Ratio | - | - | - | - | - | 1318.37 |
PS Ratio | 1.35 | 1.54 | 1.90 | 1.35 | 2.80 | 5.01 |